LRRK2 and ubiquitination

Implications for Kinase inhibitor therapy

Heather L Melrose

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pathogenic mutations and risk variants in LRRK2 (leucine-rich repeat kinase 2) represent the most common genetic cause of familial and sporadic PD (Parkinson's disease). LRRK2 protein is widely expressed throughout the brain and the periphery. Structurally, LRRK2 contains several functional domains, including a dual enzymatic core consisting of a kinase and GTPase domain. Disease-linked variants are found in both these enzymatic domains as well as in the COR [C-terminal of ROC (Ras of complex proteins)] and WD40 protein-protein binding domain. The kinase domain is widely believed to be linked to toxicity, and thus the thrust of pharmaceutical effort has focused on developing LRRK2 kinase inhibitors. However, recent data have suggested that inhibition of LRRK2 activity results in reduced LRRK2 levels and peripheral side effects, which are similar to those observed in homozygous LRRK2-knockout and LRRK2 kinase-dead rodent models. In a recent issue of the Biochemical Journal, a study led by Nichols reveals that dephosphorylation of LRRK2 cellular phosphorylation sites (Ser<sup>910</sup>/Ser<sup>935</sup>/Ser<sup>955</sup>/Ser<sup>973</sup>) triggers its ubiquitination and subsequent degradation and thus may account for the loss of function phenotypes observed in peripheral tissues in LRRK2-knockout/kinase-dead or inhibitor-treated rodents and primates. Albeit negative from a kinase inhibitor standpoint, the data open new avenues for LRRK2 biology and therapeutic approaches to counteract LRRK2 toxicity.

Original languageEnglish (US)
Pages (from-to)e21-e24
JournalBiochemical Journal
Volume470
Issue number3
DOIs
StatePublished - Sep 15 2015

Fingerprint

Ubiquitination
Leucine
Phosphotransferases
Therapeutics
Rodentia
Toxicity
ras Proteins
Phosphorylation
Proteins
GTP Phosphohydrolases
Protein Binding

Keywords

  • GNE1023
  • Kinase inhibitor
  • LRRK2
  • Parkinson's disease
  • Phosphorylation site
  • Ubiquitin

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

LRRK2 and ubiquitination : Implications for Kinase inhibitor therapy. / Melrose, Heather L.

In: Biochemical Journal, Vol. 470, No. 3, 15.09.2015, p. e21-e24.

Research output: Contribution to journalArticle

Melrose, Heather L. / LRRK2 and ubiquitination : Implications for Kinase inhibitor therapy. In: Biochemical Journal. 2015 ; Vol. 470, No. 3. pp. e21-e24.
@article{27c0e35efbf94223aa9b7de3640aa846,
title = "LRRK2 and ubiquitination: Implications for Kinase inhibitor therapy",
abstract = "Pathogenic mutations and risk variants in LRRK2 (leucine-rich repeat kinase 2) represent the most common genetic cause of familial and sporadic PD (Parkinson's disease). LRRK2 protein is widely expressed throughout the brain and the periphery. Structurally, LRRK2 contains several functional domains, including a dual enzymatic core consisting of a kinase and GTPase domain. Disease-linked variants are found in both these enzymatic domains as well as in the COR [C-terminal of ROC (Ras of complex proteins)] and WD40 protein-protein binding domain. The kinase domain is widely believed to be linked to toxicity, and thus the thrust of pharmaceutical effort has focused on developing LRRK2 kinase inhibitors. However, recent data have suggested that inhibition of LRRK2 activity results in reduced LRRK2 levels and peripheral side effects, which are similar to those observed in homozygous LRRK2-knockout and LRRK2 kinase-dead rodent models. In a recent issue of the Biochemical Journal, a study led by Nichols reveals that dephosphorylation of LRRK2 cellular phosphorylation sites (Ser910/Ser935/Ser955/Ser973) triggers its ubiquitination and subsequent degradation and thus may account for the loss of function phenotypes observed in peripheral tissues in LRRK2-knockout/kinase-dead or inhibitor-treated rodents and primates. Albeit negative from a kinase inhibitor standpoint, the data open new avenues for LRRK2 biology and therapeutic approaches to counteract LRRK2 toxicity.",
keywords = "GNE1023, Kinase inhibitor, LRRK2, Parkinson's disease, Phosphorylation site, Ubiquitin",
author = "Melrose, {Heather L}",
year = "2015",
month = "9",
day = "15",
doi = "10.1042/BJ20150785",
language = "English (US)",
volume = "470",
pages = "e21--e24",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - LRRK2 and ubiquitination

T2 - Implications for Kinase inhibitor therapy

AU - Melrose, Heather L

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Pathogenic mutations and risk variants in LRRK2 (leucine-rich repeat kinase 2) represent the most common genetic cause of familial and sporadic PD (Parkinson's disease). LRRK2 protein is widely expressed throughout the brain and the periphery. Structurally, LRRK2 contains several functional domains, including a dual enzymatic core consisting of a kinase and GTPase domain. Disease-linked variants are found in both these enzymatic domains as well as in the COR [C-terminal of ROC (Ras of complex proteins)] and WD40 protein-protein binding domain. The kinase domain is widely believed to be linked to toxicity, and thus the thrust of pharmaceutical effort has focused on developing LRRK2 kinase inhibitors. However, recent data have suggested that inhibition of LRRK2 activity results in reduced LRRK2 levels and peripheral side effects, which are similar to those observed in homozygous LRRK2-knockout and LRRK2 kinase-dead rodent models. In a recent issue of the Biochemical Journal, a study led by Nichols reveals that dephosphorylation of LRRK2 cellular phosphorylation sites (Ser910/Ser935/Ser955/Ser973) triggers its ubiquitination and subsequent degradation and thus may account for the loss of function phenotypes observed in peripheral tissues in LRRK2-knockout/kinase-dead or inhibitor-treated rodents and primates. Albeit negative from a kinase inhibitor standpoint, the data open new avenues for LRRK2 biology and therapeutic approaches to counteract LRRK2 toxicity.

AB - Pathogenic mutations and risk variants in LRRK2 (leucine-rich repeat kinase 2) represent the most common genetic cause of familial and sporadic PD (Parkinson's disease). LRRK2 protein is widely expressed throughout the brain and the periphery. Structurally, LRRK2 contains several functional domains, including a dual enzymatic core consisting of a kinase and GTPase domain. Disease-linked variants are found in both these enzymatic domains as well as in the COR [C-terminal of ROC (Ras of complex proteins)] and WD40 protein-protein binding domain. The kinase domain is widely believed to be linked to toxicity, and thus the thrust of pharmaceutical effort has focused on developing LRRK2 kinase inhibitors. However, recent data have suggested that inhibition of LRRK2 activity results in reduced LRRK2 levels and peripheral side effects, which are similar to those observed in homozygous LRRK2-knockout and LRRK2 kinase-dead rodent models. In a recent issue of the Biochemical Journal, a study led by Nichols reveals that dephosphorylation of LRRK2 cellular phosphorylation sites (Ser910/Ser935/Ser955/Ser973) triggers its ubiquitination and subsequent degradation and thus may account for the loss of function phenotypes observed in peripheral tissues in LRRK2-knockout/kinase-dead or inhibitor-treated rodents and primates. Albeit negative from a kinase inhibitor standpoint, the data open new avenues for LRRK2 biology and therapeutic approaches to counteract LRRK2 toxicity.

KW - GNE1023

KW - Kinase inhibitor

KW - LRRK2

KW - Parkinson's disease

KW - Phosphorylation site

KW - Ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=84942313644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942313644&partnerID=8YFLogxK

U2 - 10.1042/BJ20150785

DO - 10.1042/BJ20150785

M3 - Article

VL - 470

SP - e21-e24

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 3

ER -